Maze Therapeutics, Inc. (MAZE) Price & Analysis

Compare

58 Followers

MAZE Stock Chart & Stats

$38.00

Market closed

$38.00

Day’s Range― - ―

52-Week Range$6.71 - $38.49

Previous CloseN/A

VolumeN/A

Average Volume (3M)373.54K

Market Cap

$1.83B

Enterprise Value$886.88M

Total Cash (Recent Filing)$383.94M

Total Debt (Recent Filing)$24.18M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Apr 06, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.66

Shares Outstanding48,119,446

10 Day Avg. Volume464,441

30 Day Avg. Volume373,543

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)3.55

Price to Sales (P/S)4.17

P/FCF Ratio9.34

Enterprise Value/Market Cap0.49

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.37K

Enterprise Value/Ebitda-7.02

Forecast

1Y Price Target

$40.83

Price Target Upside7.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-3.21

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMaze's Phase 1 HV data from the MZE782 program showed a robust PD signal, reinforcing best-in-class potential of '782 in PKU.

Market PositionMZE829’s dual mechanism of action likely sets it apart from the current AMKD treatment landscape, potentially delaying disease progression and reversing patients out of disease.

Regulatory PathwayThe validation of proteinuria and slope as surrogate endpoints would de-risk Maze’s regulatory path and potentially shorten timelines to approval.

Bears Say

Maze Therapeutics, Inc. News

Maze Therapeutics initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Maze Therapeutics (MAZE) with a Strong Buy rating and $48 price target Maze’s...

17d ago

MAZE

Maze Therapeutics reports Q3 EPS (66c), consensus (69c)

“We are proud to have delivered another strong quarter marked by continued execution across our pipeline and business....

24d ago

MAZE

Maze Therapeutics Reports Strong Q3 2025 Progress

Maze Therapeutics, Inc. ( ($MAZE) ) has released its Q3 earnings. Here is a breakdown of the information...

18d ago

MAZE

Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc.,...

23d ago

MAZE

Maze Therapeutics Advances Kidney Disease Treatment with MZE829 Study

Maze Therapeutics, Inc. (($MAZE)) announced an update on their ongoing clinical study. Study Overview: Maze Therapeutics, Inc. is...

1M ago

MAZE

Maze Therapeutics files to sell 9.23M shares of common stock for holders

16:17 EDT Maze Therapeutics (MAZE) files to sell 9.23M shares of common stock for holders Published first on...

1M ago

MAZE

Maze Therapeutics Appoints Hervé Hoppenot as Chairman

An update from Maze Therapeutics, Inc. ( ($MAZE) ) is now available. On October 3, 2025, Maze Therapeutics,...

2M ago

MAZE

Maze Therapeutics appoints Herve Hoppenot as chairman of the board

Maze Therapeutics (MAZE) announced the appointment of Herve Hoppenot as Chairman of its Board of Directors, succeeding Charles...

2M ago

INCY

MAZE

Two new option listings on September 17th

New option listings for September 17th include Maze Therapeutics Inc (MAZE) and WhiteFiber Inc (WYFI). Published first on...

2M ago

MAZE

WYFI

Maze Therapeutics price target raised to $34 from $19 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $19 and...

3M ago

MAZE

Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $50 from $34 and keeps a...

3M ago

MAZE

Maze Therapeutics Advances Clinical Programs Amid Financial Stability

Maze Therapeutics, Inc. ( ($MAZE) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

MAZE

Maze Therapeutics price target raised to $37 from $30 at BTIG

BTIG raised the firm’s price target on Maze Therapeutics (MAZE) to $37 from $30 and keeps a Buy...

3M ago

MAZE

Maze Therapeutics price target raised to $34 from $28 at Leerink

Leerink analyst Joseph Schwartz raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $28 and...

3M ago

MAZE

MAZE FAQ

What was Maze Therapeutics, Inc.’s price range in the past 12 months?

Maze Therapeutics, Inc. lowest stock price was $6.71 and its highest was $38.49 in the past 12 months.

What is Maze Therapeutics, Inc.’s market cap?

Maze Therapeutics, Inc.’s market cap is $1.83B.

When is Maze Therapeutics, Inc.’s upcoming earnings report date?

Maze Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 127 days.

How were Maze Therapeutics, Inc.’s earnings last quarter?

Maze Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.708 by $0.048.

Is Maze Therapeutics, Inc. overvalued?

According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Maze Therapeutics, Inc. pay dividends?

Maze Therapeutics, Inc. does not currently pay dividends.

What is Maze Therapeutics, Inc.’s EPS estimate?

Maze Therapeutics, Inc.’s EPS estimate is -0.7.

How many shares outstanding does Maze Therapeutics, Inc. have?

Maze Therapeutics, Inc. has 48,119,446 shares outstanding.

What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?

Maze Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.708. Following the earnings report the stock price went down -3.476%.

Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?

Currently, no hedge funds are holding shares in MAZE

Maze Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.13%

Trailing 12-Months

Asset Growth

119.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE) is a biotechnology company focused on translating genetic insights into novel therapeutic approaches for treating a range of diseases. Operating within the biotechnology and pharmaceutical sectors, Maze leverages its proprietary COMPASS platform to identify and validate genetic modifiers, which are then developed into potential therapeutic products. The company's core focus is on discovering genetic pathways that can be modulated to treat diseases with significant unmet medical needs.

Maze Therapeutics, Inc. (MAZE) Earnings & Revenues

Historic Earnings Reports

MAZE Stock 12 Month Forecast

Average Price Target

$40.83

▲(7.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","51":"$51","18.75":"$18.75","29.5":"$29.5","40.25":"$40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18.75,29.5,40.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.91,34.22461538461538,35.53923076923077,36.85384615384615,38.168461538461536,39.48307692307692,40.79769230769231,42.112307692307695,43.426923076923075,44.74153846153846,46.05615384615385,47.37076923076923,48.68538461538462,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.91,33.51923076923077,34.128461538461536,34.737692307692306,35.346923076923076,35.956153846153846,36.565384615384616,37.17461538461538,37.78384615384615,38.39307692307692,39.00230769230769,39.61153846153846,40.22076923076923,{"y":40.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.91,32.99384615384615,33.0776923076923,33.161538461538456,33.245384615384616,33.32923076923077,33.41307692307692,33.496923076923075,33.58076923076923,33.66461538461538,33.74846153846154,33.832307692307694,33.91615384615385,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >